Mike Haney: And that really focuses on the sort of outcome, right
94% reduction in progression from pre diabetes to type 2 diabetes with tirzepatide.** **Based on a three-year clinical trial study (176-week treatment period) sponsored by Eli Lilly and Company, weekly injections of tirzepatide significantly reduced the risk of progression to type 2 diabetes by 94% in adults with prediabetes who were overweight or obese compared to placebo
doi: 10.1152/ajpgi.00024.2010 15 FehmannHCGkeRGkeB
At 3 months, members should also feel improvements in sleep, energy levels, and exercise stamina
For a research-focused look at dose levels and weight-loss studies, see Retatrutide Dosing Research
Finally, HumeCare's page describes an "exit strategy" phase once you reach your target - a personalized transition plan aimed at maintaining your results after you taper off medication, rather than assuming you'll stay on the program indefinitely
